Skip to content

Search

Showing results for "clinical trials"

Allied Health award for respiratory researcher Dr Pamela Laird

Congratulations to respiratory health clinician-researcher Dr Pamela Laird, who has won Allied Health Researcher of the Year at the WA Excellence in Allied Health Awards.

Could Perth lakes hold the key to fighting antibiotic-resistant superbugs?

Perth researchers discovered a naturally occurring virus living in the city’s waterways that could potentially fight antibiotic-resistant superbugs.

New facility to develop crucial treatment for antibiotic-resistant superbugs

Western Australia’s first bacteriophage manufacturing facility has been opened in a significant development that brings patients battling antibiotic-resistant infections a step closer to life-saving phage therapy.

New FHRI funding to support research helping kids have a healthier start to life

ORIGINS has secured $500,000 in funding from the WA Government’s Future Health Research and Innovation (FHRI) Fund.

Celebrating our final births

ORIGINS has welcomed its very last baby into the cohort

Frequently asked questions

Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).

Community engagement vital in battle against antimicrobial resistance: Wal-yan Centre to establish reference group

The Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern. 

Australia’s first draft national guideline for autism diagnosis released

Australia’s first draft national guideline for autism diagnosis has today been released for public consultation.

Telehealth

Telehealth service delivery is used extensively in allied health to provide services to individuals who are not able to attend therapy sessions face to face.

An economic case for a vaccine to prevent group A streptococcus skin infections

A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability